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eta-Blockers as First-Line
ntihypertensive Therapy
he Crumbling Continues*
arl J. Lavie, MD,† Franz H. Messerli, MD,‡
ichard V. Milani, MD†
ew Orleans, Louisiana; and New York, New York
Supposing is good but finding out is better.
—Mark Twain (1)
ver since Prichard and Gillam reported the antihyperten-
ive effect of propranolol in 1964 (2), beta-blockers (BBs)
ave been among the most prescribed drugs in the U.S. for
he treatment of hypertension (HTN) and are still recom-
ended as first-line agents by national and international
uidelines (3,4). In fact, BBs have been promoted to be used
n an equal footing with thiazide diuretics and equal or
referentially to renin angiotensin aldosterone system
RAAS) blockers or calcium-channel blockers (CCBs) for
nitial treatment of uncomplicated HTN (4–7). A closer
ook at the available evidence, however—including data
resented in this issue of the Journal (8)—casts serious
oubt regarding the efficacy of BBs compared with other
gents for the treatment of HTN (3,4,9).
See page 1154
utonomic function and resting heart rate. Many studies
ave established an elevated resting heart rate (HR) as a risk
actor for cardiovascular (CV) disease and mortality (10–
2). The importance of resting HR as a prognostic factor
nd potential therapeutic target has recently been reviewed
n detail (11). In fact, resting HR has been shown to be an
ndependent risk factor for CV morbidity and mortality for
atients without known CV disease as well as for patients
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straZeneca.ith acute myocardial infarction (MI), known coronary
eart disease (CHD), or HTN (11). Among 4,530 un-
reated patients with HTN in the Framingham Study, the
isk of CV mortality increased by nearly 70% for each
0-beats/min increase in resting HR, and all-cause mortal-
ty increased by over 2-fold (13). Similar results have been
oted in other cohorts with HTN (14,15). Clearly, chronic
mbalance of the autonomic nervous system, characterized
y activation of the sympathetic nervous system and/or
iminished vagal tone, is a marker of an unhealthy CV
ystem and is associated with increased risk of CV events
nd mortality (9,11). Conversely, nonpharmacological in-
erventions that lower HR (e.g., exercise and/or reductions
n psychological stress) reduce CV risk (10,12,16–19).
harmacologic HR lowering. In contrast to the clear
vidence of HR being an independent predictor of CV and
otal mortality in patients with and without CV disease
10–12), the benefits of pharmacologic HR slowing are
onsiderably less well-documented (15,20). As Fox et al.
11) recently reviewed, substantial data suggest that HR
eduction, even within the physiologic range, is an impor-
ant mechanism for the benefits of BBs and other HR-
owering drugs after acute MI as well as in patients with left
entricular dysfunction and heart failure (HF). In patients
ith uncomplicated HTN, however, the opposite might be
rue (15,20). In fact, Bangalore et al. (15) recently reviewed
studies with HR data in HTN, including nearly 65,000
atients, over one-half of whom were treated with BBs.
aradoxically, low HR attained in the BB group was
ssociated with a significantly higher risk for all-cause
ortality, CV mortality, MI, stroke, and HF. Theoretically,
harmacologically induced bradycardia and HTN might
ead to dyssynchrony between outgoing and reflective pulse
ave, thereby increasing central aortic pressure and the
emodynamic burden to the target organ, particularly to the
rain (15,20–22). Therefore, in contrast to patients with
I and HF, BB-associated HR reduction might actually
ncrease CV risk in patients with HTN.
otential problems with BBs. Compared with other
gents used in the treatment of uncomplicated HTN, BBs
ave a number of potential adverse effects. In fact, after 4
ecades of using BBs as primary treatment for HTN, no
tudy has shown reduced morbidity or mortality when used
s monotherapy when compared with placebo (3,4,10). In
ontrast, many meta-analyses have suggested the potential
etrimental effects of these agents. In a recent meta-analysis
f 12 studies evaluating over 90,000 patients with HTN, BB
herapy resulted in a 22% increased risk for new-onset
iabetes mellitus, a known powerful risk factor for CV
isease (23). Recent studies have focused on the epidemic in
besity (24), and therapy with BBs might be associated with
eight gain (25). One of the major long-term risks of
ong-standing HTN is HF, and prevention of HF seems to
e strongly dependent on blood pressure reduction (26).
lthough BBs might be highly effective for the treatment of
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September 22, 2009:1162–4 Beta-Blockers as First-Line Antihypertensive Therapyatients with established HF, in a meta-analysis of 12
tudies in over 100,000 patients with HTN, BBs provided
o incremental benefit for prevention of HF above and
eyond that provided by other blood pressure-lowering
herapy (26). Also, compared with other therapies for
TN, first-line therapy with BBs was associated with an
ncreased risk of stroke in elderly patients with uncompli-
ated HTN, with no significant benefits for the other CV
nd points (4,20,26). The fact that BBs might be less
ffective than other agents, not only to reduce peripheral
rterial pressure but also having less effect on the potentially
ore important central aortic pressure, might partly explain
he “pseudo-antihypertensive” effect of BBs (4,20,26,27).
eft ventricular hypertrophy (LVH) is a potent predictor of
V morbidity and mortality, and its regression seems to
ower CV risk, even independent of arterial pressure (27).
Bs—compared with RAAS blockers, CCBs, and diuret-
cs—seem to be less effective at LVH regression and, unlike
AAS blockade, do not reduce collagen content in the
yocardium (27–29).
Despite the potential detrimental effects of BBs in HTN,
t seems tempting to hypothesize that high resting HR
ould predict a greater responsiveness to BBs, resulting in a
reater reduction in major CV events. Poulter et al. (8) from
SCOT (Anglo-Scandinavian Cardiac Outcome Trial)
ssessed the impact of baseline HR on the CV event
eduction with amlodipine- versus atenolol-based therapy in
early 13,000 patients with HTN uncomplicated by base-
ine CHD. Prior studies from ASCOT have demonstrated
hat amlodipine-based therapy was superior to atenolol-
ased therapy and have even demonstrated a potentiation of
ffect between amlodipine and statin therapy (with atorva-
tatin) in the lipid-lowering arm of this trial (30,31).
nexpectedly, BB therapy did not provide greater benefit in
hose with higher resting HR, and the benefit of the
ong-acting CCB over BB was maintained regardless of
esting HR.
V benefits of amlodipine. Although the present study
dds to the evidence supporting the relative weak clinical
mpact of BBs, separating the detrimental effects of BBs
ersus the CV protection with amlodipine might be diffi-
ult. In the early 1990s considerable controversy surfaced
egarding the efficacy and safety of CCBs, particularly
elated to the unfavorable hemodynamic profile and impact
n CV events noted with the short-acting CCBs (32).
onversely, data with the long-acting CCBs, especially
mlodipine, have been impressive. In HTN, for example,
mlodipine seemed to have advantages over lisinopril for
V outcomes, particularly in black patients and women,
mong over 30,000 patients in the ALLHAT (Antihyper-
ensive and Lipid-Lowering treatment to prevent Heart
ttack Trial) (33,34). In the VALUE (Valsartan Antihy-
ertensive Long-term Use Evaluation) trial of over 15,000
atients with HTN, amlodipine and valsartan were equiv-
lent for the primary outcome, but amlodipine was signifi-
antly better than valsartan for preventing MI with a trendavoring amlodipine noted for stroke (35). In the recent
CCOMPLISH (Avoiding Cardiovascular Events through
ombined Therapy in Patients Living with Systemic Hy-
ertension) trial of over 11,000 high-risk patients with
TN, an amlodipine-benazepril combination was superior
o a hydrochlorothiazide-benazepril combination in re-
ucing CV events with a relative risk reduction of nearly of
0% (36). In addition, amlodipine has been safe and
ffective in patients with CHD (32,37), including those
ithout HTN (38), even having efficacy and safety in
atients with advanced HF (39). Therefore, long-acting
CBs have considerable efficacy and safety in the preven-
ion and treatment of CV diseases, and this evidence seems
o be particularly striking with the now-generic amlodipine
reparation.
onclusions. On the basis of the current information, how
hould clinicians currently proceed when treating patients
ith HTN? The seminal question to be asked is: “Are BBs
till alive as first-line therapy for HTN?” Certainly, BBs
rovide benefits for many CV patients (e.g., post-MI,
HD, HF, and tachyarrhythmias) regardless of level of
lood pressure. Conversely, for the patient with HTN
ithout other compelling indications, the evidence support-
ng BB therapy has vanished, although newer vasodilating
Bs (e.g., carvedilol and nebivolol) might require further
tudy (3). Thus, in response to Mark Twain (1), we no
onger need to suppose—we have found out! On the basis of
onsiderable evidence, including data in the present study
8), one can make 2 conclusions: 1) resting HR seems to be
seless as a guide to choice of antihypertensive therapy; and
) BBs seem to be equally ineffective in reducing CV events
n hypertensive patients with tachycardia as in those with
radycardia. Finally, as the evidence supporting BBs as
rst-line therapy for HTN continues to crumble, one could
nswer the question posed earlier, “Maybe alive, but barely
reathing!”
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